The latest Skyline update has a great quality of life feature for ion mobility users.
It's the new mobilogram window!
With the heatmap, you can't quite make out the bimodal distribution, but with this mobilogram, it's crystal clear.
New work from the department! In this work, Magali and team characterized the presence sialic acid-containing glycans in the widely-used B16OVA melanoma model and the expression of Siglec-E, an immunosuppressive receptor able to bind to sialic acid.
academic.oup.com/glycob/artic...
🔬Join us on the last webinar of the season on June 26th!
Featuring keynote @brookefarrugia.bsky.social and a short talk by Dr. Jessica Chitty. Dr. Alex Smith will be chairing the session.
You can register by scanning the QR code👇or here: docs.google.com/forms/d/1_Av...
I've spent the weekend catching up on #ASMS2026 talks, and this Q/A session was my highlight so far.
Context: The interested audience member was trying to shout instead of using the mic (please don't, it's hard for online people to hear the question)
Thank you @endpts.com for sharing the story about Grace Science, so close to bringing gene therapy to patients with NGly1 disease, hoping for some regulatory flexibility.
endpoints.news/grace-scienc...
Like it or lump it, the College of Experts is probably set to remain a staple of ARC's system for some time yet.
Most who serve on it report it's worth their time & effort, both as a service to the research community & for their proposal-writing abilities.
So, maybe consider nominating for it?
This banger from Matt @mattwfoster.bsky.social et al. just dropped. Love some whole blood proteomics fun, and really so much of what Matt has been doing with blood. Excellent work!
pubs.acs.org/doi/10.1021/...
Next time you hear 'glycans are just a fancy protein decoration' 😱 show them this fabulous work led by Katrine Schjoldager and team at the CGR 🇩🇰 with us 🇬🇧 showing how
The ligand preference of LRP1 is regulated by O-glycans
Out now www.science.org/doi/10.1126/...
🧵1/10 ⬇️
Chris Ashwood
Chris Ashwood
Grace Science CEO Matt Wilsey says FDA demands could kill its gene therapy for the rare and fatal NGLY1 deficiency by September without new funding or a regulatory break.
endpoints.news
If you need another reason to use proteomics to quantify proteins rather than Western Blot:
It is increasingly recognized that the ‘omic analysis of whole blood has applications for precision medicine and disease phenotyping. Despite this realization, whole blood is generally viewed as a challenging analytical matrix in comparison to plasma or serum. Moreover, proteomic analyses of whole blood have almost exclusively focused on (non)targeted analyses of protein abundances and much less on post-translational modifications (PTMs). Here, we developed a streamlined workflow for processing 20 microliters of venous blood collected by volumetric absorptive microsampling that incorporates serial trypsinization and N-glycopeptide and phosphopeptide enrichment and avoids laborious sample dry-down or cleanup steps. As many as 10,000 analytes (reported as protein groups, glycopeptidoforms, and phosphosites) can be quantified by liquid chromatography-tandem mass spectrometry in under 2 h of MS acquisition time. Using these methods, we explored the stability of “dried” and “wet” blood proteomes, as well as the effects of ex vivo inflammatory stimulus or phosphatase inhibition. Multiomics factor analysis enabled facile identification of analytes that contributed to interindividual variability of the blood proteomes, including N-glycopeptides that distinguish immunoglobulin heavy constant alpha 2 allotypes. Collectively, our results help to establish feasibility and best practices for the integrated MS-based quantification of proteins and PTMs from dried blood.
When Frontiers started automating the editorial process, I stayed. I reasoned that as long as the automation could be turned off, human editors can still ensure rigorous, high-quality peer review. This now became impossible - the system has been entirely hijacked by algorithms.
